ArticleNeuro-oncology advances

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study.

Nir Peled et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.